ClinicalTrials.gg
RecruitingNCT06025734Updated Feb 12, 2026

Transcutaneous Tibial Nerve Stimulation (TTNS) Treatment in Spina Bifida Pediatric Patients With Neurogenic Bladder

An interventional study of Transcutaneous Tibial Nerve Stimulation (TTNS) treatment in Spina Bifida, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
8 Years to 18 Years
Sex
All
01

Study summary

The purpose of this research study is to determine the effectiveness of a treatment called "transcutaneous tibial nerve stimulation" or "TTNS" in the treatment of urinary leakage for patients with spina bifida. This treatment involves electrical stimulation of a nerve by the ankle. Participants will complete urodynamic testing and questionnaires prior to the treatments. Participants will then complete 6 weekly treatments of TTNS. Participants will learn how to do the treatment in the clinic, and then can complete the treatments at home. For patients with a good response, the treatments may be continued for another 6 weeks, for a total of 6 weeks.

Read the detailed description

This study is designed to determine the outcomes of spina bifida patients with neurogenic bladder who receive Transcutaneous Tibial Nerve Stimulation (TTNS) treatment.

To identify patients that may receive the most benefit from TTNS treatment.

Patients with neurogenic bladder secondary to spina bifida with low-risk bladders, who are compliant with catheterizing, will see decreased urinary leakage and improved urodynamic parameters when used in combination with TTNS treatment.

Posterior tibial nerve stimulation via percutaneous (PTNS) or transcutaneous (TTNS) approaches have been effective in treating urinary incontinence from overactive bladder (OAB) and voiding dysfunction in adults. While the exact mechanism of action remains under evaluation, it is a standard of care for adults with OAB refractory to behavioral modifications. Studies have shown PTNS to be effective in children with overactive bladder disease and urinary retention secondary to non-neurogenic causes. TTNS has been shown to be effective for OAB symptoms in children compared to sham intervention, and further studies are ongoing. Moreover, it has been demonstrated that TTNS is non-inferior to PTNS in treating OAB in adults. TTNS is appealing due to its less invasive nature compared to PTNS.

Posterior tibial nerve stimulation implementation in the pediatric population is increasing. To date, few studies have evaluated the efficacy of posterior tibial nerve stimulation in children with spina bifida as some believe the spinal dysraphism may disrupt the mechanism of the technique. However, another form of neuromodulation, surgically-implanted sacral neuromodulation (Interstim), has been shown to be effective for urinary and bowel parameters for some patients with neurogenic bladder secondary to spina bifida. The hypothesis in the proposed study is that TTNS may benefit a subset of patients with less severe spina bifida and may be a treatment option in managing their refractory urinary incontinence.

Pre-intervention

If patient is on bladder medication(s) (anticholinergics or beta agonists), they will stop the bladder medication 2-4 weeks (minimum of 2 weeks) before pre-intervention urodynamic study (UDS)

Patient will complete 3 Day Bladder Diary at home prior to intervention (must be done at least 2 weeks after stopping bladder medications)

Patients will be provided scales for measuring diaper/pad weights at home.

At least 2 weeks after stopping bladder medications (if applicable), patient completes UDS (standard, not video) at Children's Medical Center (CMC)

At this visit, patient completes pre-intervention questionnaires (detailed below in Section 7)

Intervention Period

Intervention overview: Patients will complete weekly 30-minute sessions of TTNS. Intervention procedure described below.

The intervention period will start as 6 weeks for all patients, with extension to 12 weeks for patients who meet any of the measures of success as defined below in the "Post-intervention" section

After patient has completed pre-intervention 3 Day Bladder Diary, UDS and questionnaires, they will proceed with TTNS nursing teaching visit and the first TTNS session at Texas Scottish Rite Hospital (TSRH) or Children's Medical Center Dallas (therefore, if they have completed the Bladder Diary prior to their UDS appointment, the TTNS nursing teaching visit can be completed the same day as their UDS appointment)

At the teaching visit, patient/parent will be shown how to perform the TTNS treatment. They will then demonstrate the process of placing the electrodes and starting the treatment. The first 30-minute session will then be done at this visit. If understanding of process is demonstrated, further treatments will be done at home. If not, they will return the following week for further teaching and the second treatment. Nursing visits will be continued until proficiency is demonstrated by the patient/family, as assessed by the nurse conducting the visit.

The patient will be contacted by phone by the research team weekly after their nursing visit when proficiency was demonstrated, in order to answer questions and monitor compliance. Patients will return for additional teaching sessions as needed.

02

Conditions studied

  • Spina Bifida

Keywords

  • Pediatrics
  • Neurogenic bladder
  • TTNS
03

In context

Spinal Dysraphism

142 studies on the registry are indexed under Spinal Dysraphism; 39 are open to participants now.

This study's planned enrollment of 12 is below the median of 30 across 91 interventional studies indexed under Spinal Dysraphism.

Browse Spinal Dysraphism studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 1,010 studies on the registry; 199 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 8-18
  • Patient at TSRH
  • Diagnosis of lumbosacral spina bifida (myelomeningocele, meningocele, lipoma of spinal cord, myelocystocele, diastematomyelia, fatty/thickened filum)
  • Incontinence to compliant catheterization (compliance with catheterization as assessed by their treating provider)
  • Patient able and willing to undergo urodynamic testing without sedation
  • No surgical reconstruction with the exception of a single appendicovesicostomy (APV)
  • No Botox treatments within 1 year of enrollment
  • Patient willing and able to stop bladder medications (anticholinergics or beta agonists) 2 weeks prior to pre-intervention bladder diary, questionnaires and UDS
  • Patient lives close enough to TSRH and CMC to be willing to return for UDS, teaching, and clinic visits as detailed above
  • Patient/family speak English

Exclusion criteria

Exclusion Criteria:

  • Ages \<8 or >18
  • Diagnosis not listed above
  • Patients that have received reconstructive surgeries (i.e. augmentation or bladder neck sling) with the exception for a single APV
  • Patient received Botox treatment within 1 year of enrollment
  • Patient unable or unwilling to stop bladder medications (anticholinergics or beta agonists)
  • Patients with high-risk bladders, as assessed by their treating provider (i.e. poorly compliant bladders with high end-fill pressures)
  • Non-English speaking
  • Patients who are pregnant
  • Patients who are suspected of being pregnant
  • Patients who are nursing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    TTNS Treatment Arm

    Treatments Patient will complete 6 weeks of 30 minute treatment sessions (these can be done at home after the first teaching session) During treatments, patient may experience a tingling sensation in the foot/ankle. Patient may have discomfort in the area when first adjusting to the correct amount of stimulation for patient. Patient will have a visit with your doctor after 6 weeks of treatment at Scottish Rite. If patient have a good response to the treatments, they may be extended for another 6 weeks. After treatments Bladder diary (completed at home, on paper over a 3-day period, recording catheterization volumes and amount of leakage by weighing pads/diapers) Complete questionnaires on paper (about 10 minutes) Complete urodynamic testing at Children's Medical Center (approximately 45-60 minutes).

    Device: Transcutaneous Tibial Nerve Stimulation (TTNS) treatment

Interventions

  • DeviceTranscutaneous Tibial Nerve Stimulation (TTNS) treatment

    Spina Bifida pediatric patients with neurogenic bladder will be in Transcutaneous Tibial Nerve Stimulation (TTNS) treatment. Patient will complete 6 weeks of 30 minute treatment sessions (these can be done at home after the first teaching session)

06

What researchers measure

Primary outcomes

  1. Number of leakage episodes

    Number of leakage episodes will be measured by 3 Day Bladder Diary

    Time frame: 12 weeks

Secondary outcomes

  1. Leak weight

    Leak weight of the diapers will be measured by wet-diaper weight in grams

    Time frame: 12 weeks

  2. Number of pads used

    Number of pads used will be measured using 3-day bladder diary

    Time frame: 12 weeks

  3. Number of diapers used

    Number of diapers used will be measured using 3-day bladder diary

    Time frame: 12 weeks

  4. Quality of Life Assessment in Spina Bifida Score

    Quality of life (QoL) is measured by QUALAS assessment tool. QUALAS stands for Quality of Life Assessment of spina bifida. There are separate (but largely similar) versions for adults (QUALAS-A), children aged 8-12 (QUALAS-C) and teenagers (QUALAS-T). Each of these have further "domains" (that are scored from 0-100) that are aggregated to report quality of life scores (see below): 2 domains each for QUALAS C and T, and 3 domains for QUALAS-A. Lower scores in C and T indicate better QoL. But in QUALAS A it is mixed (Domain 1 -'Health and Relationships' : Higher scores indicate better QoL; Domain 2- 'Esteem and Sexuality' : Lower scores indicate better QoL ; Domain 3- 'Bowel and Bladder' : Lower scores indicate better QoL)

    Time frame: 12 weeks

  5. Self assessment of improvement

    Improvement will be measured quantitatively in 1-5 range where 1 reflects strong disagreement and 5 strong agreement

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06025734
Responsible party
Richard Adams (Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Sep 6, 2023
Start date
Nov 18, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 12, 2026

Study contacts

Alexandra Carolan, MD
Contact
alexandra.carlon@utsouthwestern.edu
214-456-5632
Richard Adams, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion